Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial - Behringer, K; Goergen, H; Hitz, F (The Lancet, 2015)
et al.